0.5417
price down icon9.87%   -0.0593
pre-market  Vorhandelsmarkt:  .55   0.0083   +1.53%
loading
Schlusskurs vom Vortag:
$0.601
Offen:
$0.5254
24-Stunden-Volumen:
1.49M
Relative Volume:
1.58
Marktkapitalisierung:
$30.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.16M
KGV:
-0.1824
EPS:
-2.97
Netto-Cashflow:
$-130.08M
1W Leistung:
-1.51%
1M Leistung:
-24.47%
6M Leistung:
-63.15%
1J Leistung:
-96.79%
1-Tages-Spanne:
Value
$0.5254
$0.627
1-Wochen-Bereich:
Value
$0.5254
$0.66
52-Wochen-Spanne:
Value
$0.46
$17.82

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Name
Firmenname
Alx Oncology Holdings Inc
Name
Telefon
650-466-7125
Name
Adresse
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
Mitarbeiter
80
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
ALXO's Discussions on Twitter

Vergleichen Sie ALXO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALXO
Alx Oncology Holdings Inc
0.5417 30.23M 0 -151.16M -130.08M -2.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-06 Hochstufung Jefferies Hold → Buy
2024-12-19 Herabstufung Jefferies Buy → Hold
2024-03-08 Herabstufung Stifel Buy → Hold
2023-12-08 Hochstufung Jefferies Hold → Buy
2021-12-22 Herabstufung Jefferies Buy → Hold
2021-09-30 Eingeleitet Stifel Buy
2021-05-05 Fortgesetzt Credit Suisse Outperform
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-04-06 Eingeleitet UBS Buy
2021-02-10 Eingeleitet H.C. Wainwright Buy
2020-08-11 Eingeleitet Cantor Fitzgerald Overweight
2020-08-11 Eingeleitet Credit Suisse Outperform
2020-08-11 Eingeleitet Jefferies Buy
2020-08-11 Eingeleitet Piper Sandler Overweight
Alle ansehen

Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten

pulisher
07:51 AM

ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials - Yahoo Finance

07:51 AM
pulisher
Apr 27, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Apr 27, 2025
pulisher
Apr 26, 2025

ALX Oncology faces Nasdaq delisting over price rule - Investing.com Australia

Apr 26, 2025
pulisher
Apr 26, 2025

ALX Oncology (ALXO) Stock Dips After Phase 2 Trial Setback - GuruFocus

Apr 26, 2025
pulisher
Apr 25, 2025

Evorpacept fails to meet trial endpoints in HNSCC - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology faces Nasdaq delisting over price rule By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Tr - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Sector Update: Health Care - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

Alx Oncology Holdings Inc: Rising -96.84% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology (ALXO) Reports Promising Phase 1 Trial Results for Evorpacept in B-Cell Lymphoma | ALXO Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Evorpacept fails to meet trial endpoints in HNSCC By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology Reports Promising Phase 1 Results for Evorpacept in Combination with Rituximab and Lenalidomide in B-cell Non-Hodgkin Lymphoma at AACR 2025 - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

Breakthrough: New Lymphoma Treatment Achieves 83% Complete Response Rate, Outperforming Standard Therapy - Stock Titan

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology stock falls on trial setback (ALXO:NASDAQ) - Seeking Alpha

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary Endpoints - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evalua - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology (ALXO) Shares Update After Phase 2 Trials Yield Mixed Results | ALXO Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

ALX Oncology's Evorpacept Falls Short in Dual Phase 2 Head and Neck Cancer TrialsWhat's Next? - Stock Titan

Apr 25, 2025
pulisher
Apr 13, 2025

Sei Investments Co. Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World

Apr 13, 2025
pulisher
Apr 10, 2025

ALXO stock plunges to 52-week low of $0.48 amid market challenges - Investing.com India

Apr 10, 2025
pulisher
Apr 10, 2025

ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 07, 2025

ALX Oncology advances new cancer drug into Phase 1 trials By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

ALX Oncology gets FDA nod to begin trial of ALX2004 (ALXO) - Seeking Alpha

Apr 07, 2025
pulisher
Apr 07, 2025

FDA clears ALX Oncology’s IND for ALX-2004 - BioWorld MedTech

Apr 07, 2025
pulisher
Apr 07, 2025

Alx Oncology Receives Ind Clearance From U.S. FDA For Alx2004 - marketscreener.com

Apr 07, 2025
pulisher
Apr 07, 2025

ALX Oncology advances new cancer drug into Phase 1 trials - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Breakthrough Cancer Drug Gets FDA Green Light: ALX2004 Targets Multiple Solid Tumors - Stock Titan

Apr 07, 2025
pulisher
Apr 02, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

ALXO stock touches 52-week low at $0.65 amid market challenges - Investing.com Australia

Mar 31, 2025
pulisher
Mar 21, 2025

Cantor Fitzgerald Raises Earnings Estimates for ALX Oncology - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

ALXO stock plunges to 52-week low of $0.73 amid market challenges - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

ALXO stock plunges to 52-week low of $0.73 amid market challenges By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo

Mar 20, 2025
pulisher
Mar 15, 2025

Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - MSN

Mar 15, 2025
pulisher
Mar 13, 2025

ALXO stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

ALXO stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com

Mar 12, 2025
pulisher
Mar 10, 2025

ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating - TipRanks

Mar 10, 2025
pulisher
Mar 09, 2025

Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50 - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 09, 2025

Finanzdaten der Alx Oncology Holdings Inc-Aktie (ALXO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alx Oncology Holdings Inc-Aktie (ALXO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Pons Jaume
PRESIDENT & CSO
Feb 19 '25
Sale
1.15
1,326
1,525
579,388
Lettmann Jason
CHIEF EXECUTIVE OFFICER
Feb 19 '25
Sale
1.15
2,159
2,483
170,270
Pinto Shelly
Interim CFO
Jan 06 '25
Sale
1.80
2,221
3,998
87,902
Pinto Shelly
Interim CFO
Dec 30 '24
Sale
1.58
1,426
2,253
90,123
Pons Jaume
PRESIDENT & CSO
Dec 30 '24
Sale
1.58
10,796
17,060
580,714
Hemrajani Rekha
Director
Dec 02 '24
Buy
1.55
30,000
46,404
33,000
Pinto Shelly
SVP, FINANCE AND CAO
Aug 14 '24
Sale
2.58
564
1,455
91,549
Randolph Sophia
CHIEF MEDICAL OFFICER
Aug 14 '24
Sale
2.58
1,365
3,522
325,711
Pons Jaume
PRESIDENT & CSO
Aug 14 '24
Sale
2.58
1,937
4,997
591,510
Pons Jaume
PRESIDENT & CSO
Jul 11 '24
Option Exercise
0.99
20,000
19,800
613,447
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):